Philip Morris Launches New "IQOS ILUMA i" Series Devices in Japan

PMI by 2FIRSTS.ai
Apr.19.2024
Philip Morris Launches New "IQOS ILUMA i" Series Devices in Japan
Philip Morris Japan has launched the new "IQOS ILUMA i" series devices, available online and in convenience stores nationwide.

According to Japanese media Kakaku, on April 19th, global tobacco giant Philip Morris' Japanese company launched the new "IQOS ILUMA i" series devices, which are now available for purchase online and in convenience stores.

 

According to the media report, since March 2024, the "ILUMA i" series has been available for purchase on the IQOS online store, official IQOS online accounts, and seven IQOS stores nationwide (some Yamada Denki stores, some Bic Camera stores). Starting from April 16th, major chain convenience stores and some tobacco retailers across Japan will also begin selling the product.

 

According to a statement from PMI, convenience stores will mainly sell the "ILUMA i" and "ILUMA i One", while the "ILUMA i Prime" will be exclusively available at 7-11 convenience stores starting from April 16th. All models are available in two colors: micro blue and midnight black.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Morocco Lawmakers Propose Excise Taxes on Vapes, Hookah, and Nicotine Alternatives
Morocco Lawmakers Propose Excise Taxes on Vapes, Hookah, and Nicotine Alternatives
Members of the Socialist Union of Popular Forces (USFP) have submitted amendments to Article 7 of the Finance Bill, introducing new excise taxes on e-cigarette liquids, hookah accessories, and non-tobacco nicotine products. The proposal also revises VAT exemptions and insurance tax rates to enhance fiscal fairness and revenue clarity.
Nov.11 by 2FIRSTS.ai
Australia Leads COP11 Seminars as Exploding Illicit Tobacco Market Raises Questions
Australia Leads COP11 Seminars as Exploding Illicit Tobacco Market Raises Questions
Australia sent a delegation to COP11 in Switzerland and is leading three major seminars to showcase its vape and tobacco control policies. But at home, illicit cigarette sales are skyrocketing amid record-high taxes, drawing criticism from the tobacco industry and prompting doubts over policy effectiveness.
Nov.20 by 2FIRSTS.ai
Australia TGA Warns Delivery Platforms: Don’t Promote or Supply Vapes Illegally
Australia TGA Warns Delivery Platforms: Don’t Promote or Supply Vapes Illegally
The Therapeutic Goods Administration (TGA) warned online delivery platforms not to breach Australian vape laws and said it worked with two major companies to remove non-compliant material. Under the Therapeutic Goods Act 1989, advertising vapes to the public is banned and sales are pharmacy-only; tobacconists and convenience stores cannot supply vapes. TGA will continue enforcement, with severe penalties for breaches.
Oct.30 by 2FIRSTS.ai
Lithuanian Schools Install Vape Detectors as Teen Vaping Surges
Lithuanian Schools Install Vape Detectors as Teen Vaping Surges
Over 30 Lithuanian schools have installed smart vape detectors to curb rising teen e-cigarette use. WHO data show Lithuania ranks worst among 44 countries, with 60% of 15-year-olds having tried vaping. The system alerts staff to smoke and noise changes, helping schools reduce on-campus vaping cases.
Oct.27 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai